Table 1 Nucleoside RT inhibitor-related mutation frequencies in treatment-experienced and naïve patients
Naïve | Tenofovir/Emtricitabine therapy failure | ||
|---|---|---|---|
Mutation | Mutation frequency(%) | Mutation frequency(%) | P |
V35I | 11.0 | 23.1 | 1.82 x 10 -2 |
T39A | 5.1 | 17.3 | 3.75 x 10 -3 |
M41L | 2.5 | 23.1 | 3.07 x 10 -6 |
A62V | ― | 6.7 | 4.87 x 10 -3 |
K65R | ― | 3.8 | ns |
D67N | ― | 21.2 | 1.42 x 10 -7 |
T69N | ― | 7.7 | 2.13 x 10 -3 |
K70R | ― | 14.4 | 2.02 x 10 -5 |
L74I | ― | 5.8 | 1.08 x 10 -2 |
A98G | 1.7 | 7.7 | 3.65 x 10 -2 |
K103N | 4.2 | 21.2 | 1.25 x 10 -4 |
V108I | ― | 13.5 | 3.99 x 10 -5 |
V118I | 2.5 | 13.5 | 2.46 x 10 -3 |
S162A | 8.5 | 1.9 | 3.59 x 10 -2 |
Q174R | ― | 5.8 | 1.09 x 10 -2 |
V179I | 2.5 | 10.6 | 1.57 x 10 -2 |
Y181C | ― | 17.3 | 2.47 x 10 -6 |
M184V | 0.8 | 42.3 | 1.76 x 10 -14 |
G190A | ― | 15.4 | 1.00 x 10 -5 |
H208Y | ― | 9.6 | 5.99 x 10 -4 |
L210W | 0.8 | 18.3 | 6.23 x 10 -6 |
L214F | 79.7 | 91.3 | 1.65 x 10 -2 |
T215F | ― | 10.6 | 3.05 x 10 -4 |
T215Y | ― | 19.2 | 6.00 x 10 -7 |
K219E | ― | 7.7 | 2.14 x 10 -3 |
K219Q | 0.8 | 9.6 | 2.89 x 10 -3 |
K223E | ― | 4.8 | 2.44 x 10 -2 |
L228H | ― | 9.6 | 6.02 x 10 -4 |
L228R | ― | 7.7 | 2.16 x 10 -3 |
R284K | 2.5 | 9.6 | 2.87 x 10 -2 |
V292I | 11.0 | 21.2 | 4.49 x 10 -2 |
E297K | 19.5 | 35.6 | 7.82 x 10 -3 |
G333E | 6.8 | 15.4 | 4.60 x 10 -2 |